SUN-087 FGFR-Selective Tyrosine Kinase Inhibitors, Such as Infigratinib, Show Potency and Selectivity for FGFR3 at Pharmacologically Relevant Doses for the Potential Treatment of Achondroplasia

BACKGROUND: Germline mutations in fibroblast growth factor receptor (FGFR) genes 1-3 can cause skeletal dysplasias and craniosynostoses. Achondroplasia (ACH), the most common form of disproportionate short stature, is caused primarily by an autosomal dominant G380R substitution in FGFR3 [Horton WA e...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobscha, Katherine, Wei, Ge, Dambkowski, Carl L, Rogoff, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208687/
http://dx.doi.org/10.1210/jendso/bvaa046.558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208687/
http://dx.doi.org/10.1210/jendso/bvaa046.558

Ejemplares similares